Study compares renoprotective effects of metabolic bariatric surgery, GLP-1RA
Editor's Note For diabetic patients with obesity and chronic kidney disease (CKD), metabolic bariatric surgery could protect the kidneys better than therapy with glucagon-like peptide-1 receptor agonists (GLP-1RA), according to research published in the September issue of the Annals of Surgery. Conducted at a large US health system, the study…
Healthcare costs projected to reach new high in 2025
Editor's Note Healthcare costs are expected to rise between 7% and 8% in 2025, according to a report from PwC's Health Research Institute. As detailed in a July 17 article from Fierce Healthcare, PwC projections for an 8% increase in the group market and 7.5% in the individual market would…
Study: Bariatric surgery outperforms GLP-1 treatment, lifestyle modifications
Editor's Note Bariatric surgery provides longer-lasting, more effective weight loss than GLP-1 receptor agonists and lifestyle interventions, according to systematic reviews of medical literature from 2020 to 2024. Medical Xpress reported the news June 11. Presented at the American Society for Metabolic and Bariatric Surgery (ASMBS) 2024 Annual Scientific Meeting,…
Study: standard preoperative fasting guidelines safe for GLP-1 patients
Editor's Note Preoperative use of GLP-1 receptor agonists (RA) medications such as Ozempic and Wegovy is safe, according to a study published in the June issue of the American Journal of Gastroenterology. Controversy has swirled around these drugs due to the risk of slowed stomach emptying increasing a patient’s odds…
Study: Ozempic slows disease, reduces cardiovascular risk in CKD, diabetes patients
Editor's Note Semaglutide, the active ingredient in Ozempic diabetes treatment and Wegovy weight-loss treatment, outperformed a placebo and demonstrated capacity to reduce risk of death from kidney-related or cardiovascular causes in a recent study of patients with type 2 diabetes and chronic kidney disease spearheaded by manufacturer Novo Nordisk. Published…
Study: Weight-loss drug semaglutide boosts repeat surgery risk
Editor's Note Popular weight-loss \ drug semaglutide could significantly increase risk for repeat operations patients with diabetes who undergo lumbar surgery. According to a May 8 report in Medscape Medical News, the findings are pending review for publication and reportedly provides the first evidence on the impact of semaglutide on…
Free Daily News
- Milestone pig kidney transplant offers hope amid ethical, safety questions
- Fitch Ratings: Hospital credit outlook improves amid stabilizing margins
- Annual Leapfrog Group awards recognize top hospitals, ASCs
- US obesity rates decline for first time in a decade
- Study: Active monitoring without surgery safe for certain low-risk DCIS patients
- Data support option to skip sentinel lymph node biopsy in early breast cancer
- Surveyed nurses, physicians likely to quit
- Costs drop, access expands for GLP-1 weight loss drugs
- Q&A: Perioperative immunotherapy advances for early-stage NSCLC
- Proposals close December 16: Present at the 2025 OR Manager Conference